H.R.2872 - Access to Life-Savings Therapies Act102nd Congress (1991-1992)
|Sponsor:||Rep. Campbell, Tom [R-CA-12] (Introduced 07/11/1991)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 07/26/1991 Referred to the Subcommittee on Health and the Environment. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Summary: H.R.2872 — 102nd Congress (1991-1992)All Information (Except Text)
Introduced in House (07/11/1991)
Access to Life-Saving Therapies Act - Amends the Federal Food, Drug, and Cosmetic Act to direct the Secretary of Health and Human Services, through the Food and Drug Administration, to approve, at the request of the sponsor and on an expedited basis, a drug or biologic needed to treat or prevent a life threatening disease or seriously debilitating illness if the drug or biologic meets certain conditions, including some indications of effectiveness and safety and a lack of alternative satisfactory therapy. Deems an application under the amendments made by this Act approved unless other action is taken within 120 days.
Prohibits any health insurance policy or plan from distinguishing, for the purpose of determining whether a drug is eligible for coverage or reimbursement, between a drug approved under the amendments made by this Act and one approved under specified other provisions of the Public Health Service Act.
Mandates suspension of approval under the amendments made by this Act if at least two subsequent studies fail to confirm the initial safety and efficacy conclusions.
Requires written informed consent for administration of a drug approved under amendments made by this Act.